Halle (Saale), 23.05.2022. Antimicrobial resistance continues to be on the rise despite increased public awareness. According to a study published in The Lancet, resistant germs were directly responsible for 1.27 million deaths worldwide and played a part in 3.68 million additional deaths [Murray et al., 2022]. One of the main causes of rising resistance is incautious prescription behavior by physicians, as well as the use of antibiotics by patients themselves. Interestingly, more than every 8th antibiotic is prescribed by dentists [zm online, 2022]. PerioTrap's contribution to the solution of this global societal challenge lies on the one hand in the development of local dosage forms: Due to their dosing they provoke lower resistances and at the same time do not trigger systemic resistance effects (e.g. in infectious co-morbidities). On the other hand, PerioTrap is developing highly specific active substances that are directed exclusively against pathogenic germs and their virulence, therefore, possibly avoiding the use of important broad-spectrum antibiotics. PerioTrap has now been awarded a third publicly funded project by IB Sachsen-Anhalt to test these substance’s preclinical safety and efficacy with the help of further project partners.
Halle (Saale), 23.11.2021. PerioTrap has received the official statement of its first Scientific Advisory Board Meeting which was held on October 19th at the company’s offices.
The board consists of leaders and experts in the field of drug design, periodontitis fundamental and clinical research, microbiology as well as pharmaceutical technology. The shared feedback of its internal discussion endorses PerioTrap’s Research Program which was found to be “up and running in a remarkable short time frame. Both drug programs showed significant progress in the last year.”
Dr. Mirko Buchholz, CSO and Co-Founder of PerioTrap Pharmaceuticals states: “We are very happy to welcome these highly recognized experts of the periodontal and drug development fields and to share with them our latest research advancements. To receive such a positive opinion and advice makes us proud and very much confirms us to keep following our route of development.”
PerioTrap’s longterm release formulation of minocycline is about to enter clinical testing while its new chemical entity that addresses the microbiome shift in periodontitis is currently being tested in vivo. In general, it is being advised to stay focused to achieve the next critical milestones.
If you would like to learn more about our programs check out our latest publications.
Halle (Saale), 16.08.2021. Infectious diseases are often treated with broadband antibiotics that act against a great range of bacteria. The systemic application of antibiotics always has a negative impact of the person’s body, frequently noticeable by side effect on the gastrointestinal tract. In cases like periodontitis, where keystone pathogens disrupt the homoeostasis of a well balanced and diverse microbiota, the eradication of the majority of bacteria poses an even a greater risk. A recurrence of the pathology is almost inevitable if the oral microbiota stays in dysbiosis as pathogens are more likely to colonize when beneficial effects of the commensals are missing. In order to deliver targeted treatments against the disease-causing pathogens, PerioTrap has now been awarded two public grants by the German Federal State of Saxony-Anhalt, AMEPA and ParoStop, with money from the European Regional Development Fund (ERDF). The received funding will be used to progress PerioTrap’s inhibitors and the according delivery technology that ensures a sustained drug release at the site of infection into regulatory stages.